Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
Healthcare
$3.53 -3.40%
-$0.24 today
- Market cap
- $103.02M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
52W Low $3.71High $8.74
Volume 0.86M
Average 0.65M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$29.52M
FY 2025 · Annual
Net Income
-$26.55M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 951K | 675K | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 572K |
| Gross Profit | 0 | 951K | 675K | 0 | (572K) |
| Gross Margin | — | 100.0% | 100.0% | — | — |
| Research & Development | 6.08M | 12.44M | 12.9M | 20.01M | 9.12M |
| Selling, General & Admin | 2.9M | 6.57M | 8.55M | 12.1M | 20.4M |
| Operating Expenses | 8.98M | 19M | 21.45M | 32.12M | 28.95M |
| Depreciation & Amortization | 13K | 161K | 284K | 428K | 572K |
| EBITDA | (9.38M) | (17.89M) | (30.18M) | (36.23M) | (25.91M) |
| EBITDA Margin | — | -1881.3% | -4470.8% | — | — |
| Operating Income | (8.98M) | (18.05M) | (20.77M) | (32.12M) | (29.52M) |
| Operating Margin | — | -1898.2% | -3077.6% | — | — |
| Interest Income | 0 | 0 | 615K | 1.26M | 1.01M |
| Interest Expense | 628K | 6K | 82K | 71K | 71K |
| Other Income / Expenses | (1.04M) | (6K) | (9.77M) | (4.61M) | 2.96M |
| Income Before Tax | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Pre-Tax Margin | — | -1898.8% | -4525.0% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Net Margin | — | -1898.8% | -4525.0% | — | — |
| EPS (Basic) | (8.60) | (1.20) | (1.28) | (5.60) | (1.67) |
| EPS (Diluted) | (8.60) | (1.20) | (1.28) | (5.60) | (1.67) |
| 1.17M | 1.51M | 2.45M | 6.7M | 158.87M | |
| 1.17M | 1.51M | 2.45M | 6.7M | 158.87M |
UNCY Earnings Waterfall · TTM
NASDAQ:UNCY · Revenue to Net Income
Key Ratios
EPS$-1.71
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-13.0
P/S Ratio0.0
Analysis
$0 of revenue converted into -$39.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.71, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 29, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 1, 2026 | |
| 8-K | Current report | Sep 29, 2026 | |
| 8-K | Current report | Sep 28, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 |
How much revenue does UNCY generate?
Unicycive Therapeutics, Inc. (UNCY) reported $0.00 of revenue in fiscal 2025.
Is UNCY profitable?
Unicycive Therapeutics, Inc. (UNCY) reported -$26.55M of net income.
Continue the stock analysis
Jump to another research area for this company.